Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 7.7%
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 7.7%
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $13.71 and last traded at $13.71. 56,476 shares changed hands during trading, a decline of 82% from the average session volume of 305,858 shares. The stock had previously closed at $14.85.
米納利藥物治療有限公司(NASDAQ:MLYS-獲取評級)股票在周二中間交易期間下跌了 7.7%。該公司的交易價格低至 13.71 美元,最後交易價為 13.71 美元。56,476 股股份在交易過程中轉手,較 305,858 股平均交易量下跌 82%。該股票之前已收盤 14.85 美元。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of analysts recently issued reports on the stock. Bank of America began coverage on shares of Mineralys Therapeutics in a research report on Tuesday, March 7th. They set a "buy" rating and a $39.00 target price for the company. Wells Fargo & Company began coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "overweight" rating and a $27.00 price target for the company. Evercore ISI began coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "outperform" rating for the company. Credit Suisse Group decreased their price target on Mineralys Therapeutics from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Thursday, March 16th. Finally, Stifel Nicolaus initiated coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued a "buy" rating and a $45.00 price target for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $36.20.
一些分析師最近發布了有關股票的報告。美國銀行開始覆蓋 Mineralys 治療藥物的股票上週二的研究報告, 3 月 7 日.他們為該公司設定了「購買」評級和 39.00 美元的目標價格。富國銀行 & 公司開始覆蓋 Mineralys 治療藥物在週二的報告, 3 月 7 日.他們為該公司頒布了「超重」評級和 27.00 美元的目標價格。永可 ISI 開始覆蓋礦物質藥物治療在週二的報告, 3 月 7 日.他們為公司發出了「跑贏大市」評級。瑞信集團將 Mineralys 治療藥物的價格目標從 $40.00 降至 38.00 美元,並在 3 月 16 日(星期四)的一份報告中為該公司設定了「跑贏」評級。最後, 斯蒂菲爾尼古拉斯開始覆蓋礦物質治療藥物在星期二的報告, 3 月 7 日.他們為該公司發布了「買入」評級和 45.00 美元的目標價格。六位投資分析師對該股票進行了買入評級進行了評級,根據 MarketBeat 的數據,該股票的平均評級為「買入」,共識目標價為 36.20 美元。
Mineralys Therapeutics Price Performance
礦物質藥物治療價格表現
Insider Activity at Mineralys Therapeutics
礦物質藥物治療的內幕活動
In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the company's stock in a transaction that occurred on Tuesday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at approximately $29,875,664. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the company's stock in a transaction that occurred on Tuesday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at approximately $29,875,664. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Scott Levy purchased 6,250 shares of the company's stock in a transaction that occurred on Tuesday, February 14th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $100,000.00. Following the completion of the transaction, the chief financial officer now owns 350,811 shares in the company, valued at approximately $5,612,976. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 1,568,750 shares of company stock valued at $25,100,000.
在其他消息, 主任鐳資本管理, L.P. 在發生在 2 月 14 日星期二的交易購買了該公司的股票 1,250,000 股.這些股份以每股 16.00 美元的平均成本收購,總價值為 20 萬美元。交易完成後,董事現擁有該公司 1,867,229 股股份,價值約為 29,875,664 美元。該交易在與 SEC 合法提交的文件中披露,可通過以下方式訪問 這個鏈接。在其他消息, 主任鐳資本管理, L.P. 在發生在 2 月 14 日星期二的交易購買了該公司的股票 1,250,000 股.這些股份以每股 16.00 美元的平均成本收購,總價值為 20 萬美元。交易完成後,董事現擁有該公司 1,867,229 股股份,價值約為 29,875,664 美元。該交易在與 SEC 合法提交的文件中披露,可通過以下方式訪問 這個鏈接。此外,首席財務官亞當·斯科特·利維購買了 6,250 該公司股票的股票在星期二發生的交易,2 月 14 日。這些股份以每股 16.00 美元的平均成本購買,總交易額為 10 萬美元。交易完成後,首席財務官現在擁有該公司的 350,811 股股份,價值約為 5,612,976 元。可以找到此次購買的披露 這裡。在過去九十天內,內部人士已經購買了 1,568,750 股價值 25 億美元的公司股票。
About Mineralys Therapeutics
關於礦物療法
(Get Rating)
(取得評分)
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc is based in RADNOR, Pa.
Mineralys Theraptics Inc 是一家臨床階段的生物製藥公司,專注於開發針對異常升高醛固酮驅動的疾病的藥物。礦物療法公司總部位於賓夕法尼亞州 RANOR。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Mineralys Therapeutics (MLYS)
- Game-Changing News For Tesla Investors
- DOW New Hghs Coming Sooner Than Later
- The Tide Is Turning For Harley-Davidson
- Why did Sarepta Therapeutics Stock Plummet?
- Microsoft Is The New Safe Haven
- 獲取有關礦物療法研究報告的免費副本
- Tesla 投資者的改變遊戲規則
- 陶氏指數新 HGHS 比以後更早推出
- 潮汐正在轉向哈雷戴維森
- 為什麼薩雷普塔治療藥物股票下跌?
- 微軟是新的避風港
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收礦物質藥物治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Mineralys 治療和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。